title: Live attenuated vaccine: the first clinically approved dengue vaccine?
abstract: Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. There are 390 million human infections each year, with 96 million infections exhibiting disease symptoms. Currently, there is no clinically approved vaccine and antiviral for DENV. The four serotypes of DENV (DENV-1, -2, -3 and -4) have 25-40% variation at the amino acid level. Such variation has posed challenges for the development of a tetravalent vaccine and therapeutics.
authors.affiliation: Singapore Immunology Network, Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore.
authors.forename: Katja
authors.initials: K
authors.lastname: Fink
authors.forename: Pei-Yong
authors.initials: PY
authors.lastname: Shi
mesh_terms: D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D003716:Dengue Virus / Q000145:classification / Q000276:immunology; D017277:Drug Approval; D006801:Humans; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D053059:Dengue Vaccines; D014613:Vaccines, Attenuated